We have located links that may give you full text access.
Critical decisions in selecting an intravenous immunoglobulin product.
Use of intravenous immunoglobulin (IVIG) therapy has expanded enormously in the past two to three decades, targeting a large number of autoimmune and inflammatory disorders as well as primary immunodeficiency disease, human immunodeficiency virus, and Kawasaki disease. Increased use, particularly at higher doses and in older patients, has presented certain challenges related to safety and tolerability. All IVIGs are not the same. They differ in manufacturing processes, methods of virus elimination, and final composition. Carefully evaluating patient risk factors and matching them to potential IVIG product risks and benefits are becoming increasingly important in the selection of a particular IVIG.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app